IN2014MN02060A - - Google Patents

Info

Publication number
IN2014MN02060A
IN2014MN02060A IN2060MUN2014A IN2014MN02060A IN 2014MN02060 A IN2014MN02060 A IN 2014MN02060A IN 2060MUN2014 A IN2060MUN2014 A IN 2060MUN2014A IN 2014MN02060 A IN2014MN02060 A IN 2014MN02060A
Authority
IN
India
Prior art keywords
amino acid
amount
clinical condition
biological material
index value
Prior art date
Application number
Other languages
English (en)
Inventor
Kenji Hamase
Yousuke Toujo
Masashi Mita
Chieko Mizumoto
Original Assignee
Univ Kyushu Nat Univ Corp
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyushu Nat Univ Corp, Shiseido Co Ltd filed Critical Univ Kyushu Nat Univ Corp
Publication of IN2014MN02060A publication Critical patent/IN2014MN02060A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/89—Inverse chromatography
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8818—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8877—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2060MUN2014 2012-03-18 2013-03-18 IN2014MN02060A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012061305 2012-03-18
PCT/JP2013/001849 WO2013140785A1 (ja) 2012-03-18 2013-03-18 疾患サンプル分析装置、分析システム及び分析方法

Publications (1)

Publication Number Publication Date
IN2014MN02060A true IN2014MN02060A (zh) 2015-08-21

Family

ID=49222264

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2060MUN2014 IN2014MN02060A (zh) 2012-03-18 2013-03-18

Country Status (7)

Country Link
US (2) US20150079623A1 (zh)
EP (3) EP3795997B1 (zh)
JP (3) JP6037388B2 (zh)
CN (11) CN110133299A (zh)
IN (1) IN2014MN02060A (zh)
TW (2) TWI615614B (zh)
WO (1) WO2013140785A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015087985A1 (ja) 2013-12-11 2015-06-18 株式会社資生堂 腎不全の早期診断マーカー
SG10201911910RA (en) * 2015-06-10 2020-02-27 Univ Kanazawa Disease-state biomarker for renal disease
CN105154487B (zh) * 2015-10-10 2019-03-05 中国科学院南海海洋研究所 氨基转移酶和异构酶在催化形成L-allo-Ile中的应用
JP6609282B2 (ja) * 2016-05-17 2019-11-20 国立大学法人大阪大学 糖尿病を判定するための血液試料の分析方法及びシステム
JP7123329B2 (ja) * 2016-05-17 2022-08-23 国立大学法人大阪大学 腎臓病の予後予測方法及びシステム
EP3543690A4 (en) 2016-11-15 2020-05-27 Shiseido Company, Ltd. MULTI-DIMENSIONAL CHROMATOGRAPHIC ANALYSIS PROCESS AND ANALYSIS SYSTEM
JPWO2018159833A1 (ja) * 2017-03-02 2020-01-16 株式会社ニコン 細胞の判別方法、がんの検査方法、計測装置、がんの検査装置および検査プログラム
US20200002322A1 (en) 2017-03-03 2020-01-02 Shiseido Company, Ltd. Novel compound, fluorescence derivatization reagent including said novel compound, method for optically resolving optical isomer of amino acid in which said novel compound is used, and fluorescence derivatized amino acid
JP7364166B2 (ja) * 2018-06-07 2023-10-18 国立大学法人金沢大学 腎障害の予防又は治療用の医薬組成物
WO2020045364A1 (ja) * 2018-08-27 2020-03-05 株式会社 資生堂 乾癬を判定するための皮膚試料の分析方法及びシステム
JP7434678B2 (ja) 2019-05-20 2024-02-21 花王株式会社 認知症又はそのリスクの検査方法
JP6993654B2 (ja) 2019-12-27 2022-02-15 Kagami株式会社 腎機能を推定する方法及びシステム
CN112180007B (zh) * 2020-09-16 2023-08-18 上海市皮肤病医院 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
CN111899883B (zh) * 2020-09-29 2020-12-15 平安科技（深圳）有限公司 少样本或零样本的疾病预测设备、方法、装置及存储介质
WO2023033178A1 (ja) * 2021-09-03 2023-03-09 Kagami株式会社 癌についての情報を提供する方法、癌についての情報を提供するシステム及び癌を治療する方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4290893A (en) * 1979-05-08 1981-09-22 Yeda Research & Development Co. Ltd. Separation of amino acids by liquid chromatography using chiral eluants
CA2030212A1 (en) * 1989-11-22 1991-05-23 Judson V. Edwards Peptides
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
JPH0975078A (ja) * 1995-09-13 1997-03-25 Ikeda Shokken Kk 耐熱性ｄ−アミノ酸オキシダーゼ、その製造法および微生物
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
EP0882736A1 (en) * 1997-06-02 1998-12-09 Laboratoire Theramex S.A. LH-RH peptide analogues, their uses and pharmaceutical compositions containing them
AU743112B2 (en) * 1998-06-11 2002-01-17 Fox Chase Cancer Center Method for assessing a diabetic's risk of experiencing a diabetes-associated pathologic condition
EP1183521B1 (en) * 1999-05-14 2014-03-19 Brandeis University Aptamer-based detection
US6479063B2 (en) * 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
CA2475953A1 (en) * 2002-02-27 2003-09-04 E. Ann Tallant Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
GB0223424D0 (en) * 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
WO2004052191A1 (ja) * 2002-12-09 2004-06-24 Ajinomoto Co., Inc. 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体
CN1761680A (zh) * 2002-12-26 2006-04-19 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
AU2003900777A0 (en) * 2003-02-21 2003-03-13 Medvet Science Pty. Ltd. A method of diagnosis and treatment
WO2004081527A2 (en) * 2003-03-10 2004-09-23 Sionex Corporation Systems for differential ion mobility analysis
US20060217316A1 (en) * 2003-04-02 2006-09-28 Ragab El-Rashidy Method for the treatment of prostate cancer
JP4291628B2 (ja) 2003-06-12 2009-07-08 株式会社資生堂 液体クロマトグラフ装置及び試料に含まれる光学異性体の分析方法
CN1557823A (zh) * 2004-02-12 2004-12-29 窦德献 L-或d-氨基酸合铂配位体、制备方法及其用途
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
GB0417887D0 (en) * 2004-08-11 2004-09-15 Ares Trading Sa Protein
WO2006098523A1 (ja) * 2005-03-18 2006-09-21 Shiseido Company, Ltd. 扁平上皮細胞癌関連抗原を指標とする皮膚性状の評価方法
CN101189243A (zh) * 2005-04-06 2008-05-28 阿斯利康(瑞典)有限公司 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用
JP2007077104A (ja) * 2005-09-16 2007-03-29 Shiseido Co Ltd 血管内皮増殖因子阻害剤
BRPI0708485A2 (pt) * 2006-03-02 2011-05-31 Perkinelmer Las Inc métodos para distinguir isÈmeros usando espectrometria de massa
US20070258899A1 (en) * 2006-03-31 2007-11-08 Karyon-Ctt Ltd Diagnostic and therapeutic agents
JP5005955B2 (ja) * 2006-05-24 2012-08-22 田辺三菱製薬株式会社 被験物質の脂質代謝異常症誘発可能性を予測する方法
WO2008005469A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
EP1900742A1 (en) * 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
BRPI0716190A2 (pt) * 2006-09-06 2013-11-12 Aeterna Zentaris Gmbh Conjugados de disorazóis e seus derivados com móleculas de ligação celular, derivados de disorazol, processos para fabricação e uso dos mesmos
US20090075284A1 (en) * 2006-09-19 2009-03-19 The Regents Of The University Of Michigan Metabolomic profiling of prostate cancer
JP2010516697A (ja) * 2007-01-18 2010-05-20 セプラコール インク． Ｄ−アミノ酸オキシダーゼ阻害剤
CN101688177A (zh) * 2007-02-12 2010-03-31 人类起源公司 来自贴壁胎盘干细胞的肝细胞和软骨细胞；以及cd34+、cd45-胎盘干细胞富集的细胞群
US8034780B2 (en) * 2007-07-16 2011-10-11 Mcphail Kerry Leigh Isolation, purification, and structure elucidation of the antiproliferative compound coibamide A
US20110045495A1 (en) * 2008-01-17 2011-02-24 Yoshinori Tanaka Composition and method for diagnosis or detection of renal cancer
JP2009184981A (ja) * 2008-02-07 2009-08-20 Shiseido Co Ltd 抗ｄ−アミノ酸モノクローナル抗体及び、抗ｄ−アミノ酸モノクローナル抗体を用いたｄ−アミノ酸の免疫学的分析方法
CN102149725A (zh) * 2008-05-14 2011-08-10 三井有限公司 用于抑制g2细胞周期停滞和使细胞对dna损伤剂敏感的cbp501衍生制剂及基于其的方法
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US20110311650A1 (en) * 2008-07-07 2011-12-22 Thomas Wang Multiplexed biomarkers of insulin resistance
JP2010038796A (ja) * 2008-08-06 2010-02-18 Human Metabolome Technologies Inc 疾患マーカー、および、疾患マーカーの測定方法
JP5639890B2 (ja) * 2008-08-26 2014-12-10 国立大学法人九州大学 Ｄａｏ１−／−マウスを活用したＤ−アミノ酸関連疾患の評価・スクリーニング方法
WO2010057647A2 (en) * 2008-11-21 2010-05-27 Universita' Degli Studi Di Milano Methods and compositions for the diagnosis and treatment of diabetes
ES2799327T3 (es) * 2009-05-05 2020-12-16 Infandx Ag Método para diagnosticar asfixia
CN101619092B (zh) * 2009-08-06 2012-08-15 中国人民解放军第三军医大学第二附属医院 肿瘤抗原trag-3模拟表位肽及其应用
CN102079771B (zh) * 2010-12-10 2012-10-03 郑州大学 具有抗肿瘤活性的雌甾氨基酸酯化合物及其合成方法

Also Published As

Publication number Publication date
US20190025320A1 (en) 2019-01-24
JP6037388B2 (ja) 2016-12-07
JP2017015741A (ja) 2017-01-19
TWI615614B (zh) 2018-02-21
JP6391787B2 (ja) 2018-09-19
CN110133297A (zh) 2019-08-16
JP2017223711A (ja) 2017-12-21
CN110133300B (zh) 2022-02-25
CN114966050A (zh) 2022-08-30
CN104246497B (zh) 2017-10-13
EP3663758A1 (en) 2020-06-10
CN110133300A (zh) 2019-08-16
CN110133301A (zh) 2019-08-16
CN110133296A (zh) 2019-08-16
CN104246497A (zh) 2014-12-24
TW201736851A (zh) 2017-10-16
US20150079623A1 (en) 2015-03-19
CN110161256A (zh) 2019-08-23
EP2829877B1 (en) 2020-01-22
EP3795997B1 (en) 2022-08-24
CN107449923A (zh) 2017-12-08
CN110133296B (zh) 2022-03-25
TWI664425B (zh) 2019-07-01
CN110133298A (zh) 2019-08-16
CN107449923B (zh) 2020-07-24
TW201344194A (zh) 2013-11-01
EP3795997A1 (en) 2021-03-24
CN110133299A (zh) 2019-08-16
EP2829877A4 (en) 2015-12-09
CN110161256B (zh) 2022-03-25
CN110133295A (zh) 2019-08-16
EP2829877A1 (en) 2015-01-28
WO2013140785A1 (ja) 2013-09-26
JP6214016B2 (ja) 2017-10-18
CN110133301B (zh) 2022-03-22
JP2013224929A (ja) 2013-10-31

Similar Documents

Publication Publication Date Title
IN2014MN02060A (zh)
HK1203622A1 (zh) 基於包含分析物的樣品的感測物理特性和導出的生物傳感器參數的電化學測試條的精確分析物測量
BR112015003715A8 (pt) análise de raman, de infravermelho, ou de raman-infravermelho da estrutura de proteína de plasma de sangue periférico e sua relação para desenvolvimento cognitivo no mal de alzheimer
GB2488700B (en) Methods for monitoring disease conditions by analysis of the full repertoire of CDR3 sequences of an individual
MX348392B (es) Sistemas y metodos para diagnostico de la salud.
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
IN2014DN10121A (zh)
WO2014074835A3 (en) Antibody compositions and immunoassay methods to detect isoforms of anti-mullerian hormone
EP3264090A3 (en) Method for detecting nucleosome adducts
EP2566983A4 (en) SERIAL ANALYSIS OF BIOMARKERS FOR THE DIAGNOSIS OF A DISEASE
WO2013040099A3 (en) Sepsis prognosis biomarkers
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
EP2573192A4 (en) METHOD AND KIT FOR DIAGNOSING DISEASE ASSOCIATED WITH AIM
WO2011144718A3 (en) Methods and kits for diagnosing colorectal cancer
MX2014003988A (es) Sistema de monitoreo para monitorear un paciente y detectar delirio del paciente.
MX2011013916A (es) Aparato de analisis continuo y sistema de control de componente de muestra.
TN2015000161A1 (en) Methylglyoxal as a marker of cancer
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
WO2009001545A1 (ja) 移植片対宿主疾患の検査および治療方法
PH12015500519A1 (en) Mitochondrial toxicity test
MX2018001697A (es) Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores.
MX2012007009A (es) Método para diagnosticar un tumor maligno.
WO2010099137A3 (en) In situ methods for monitoring the emt status of tumor cells in vivo
EP1898215A4 (en) METHOD FOR ANALYZING ENDOCRINE SUBSTANCE IN A SPECIMEN
HK1136873A1 (en) Use of nnmt as a marker for lung cancer